Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Invitae (NVTAQ)
OTHER OTC:NVTAQ
Invitae (NVTAQ) Stock Price & Analysis
3,300 Followers
NVTAQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range<$0.01 - $1.66
Previous Close$0.01
Volume311.69K
Average Volume (3M)3.05M
Market Cap
$143.25K
Enterprise Value$1.06B
Total Cash (Recent Filing)$254.57M
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)>-0.1
Beta-23.57
Next Earnings
Aug 06, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.38
Shares Outstanding286,492,840
10 Day Avg. Volume282,110
30 Day Avg. Volume3,053,478
Standard Deviation0.29
R-Squared0.08
Alpha-0.09
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.05
Enterprise Value/Ebitda-0.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Invitae News
PremiumCompany Announcements
Invitae Nears Asset Sale to Labcorp Amid Bankruptcy Process
PremiumCompany Announcements
Invitae Submits Unaudited February Operating Report with Caution
PremiumCompany Announcements
Invitae Releases Preliminary Financial Results for 2023Bulls Say, Bears Say
Bulls Say
Earnings3Q results show sales in line with expectations, expanding gross margins, and reduced cash burn.
Management StrategyManagement is actively exploring numerous options to ensure future viability and achieve sales acceleration.
Segment PerformanceOncology and Women's Health segments were ahead of forecasts.
Bears Say
Asset ValuationThe company impaired substantially all of its long-lived intangible assets, resulting in a significant charge in the third quarter.
Financial HealthThe new going concern qualification in the 10Q indicates substantial doubt in the company's future viability.
Financial HealthThe new going concern qualification in the 10Q signals substantial doubt in the company's future viability.
---
Ownership Overview
5.91% Insiders
10.23% Mutual Funds
0.40% Other Institutional Investors
83.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVTAQ FAQ
What was Invitae’s price range in the past 12 months?
Invitae lowest stock price was <$0.01 and its highest was $1.66 in the past 12 months.
What is Invitae’s market cap?
Currently, no data Available
When is Invitae’s upcoming earnings report date?
Invitae’s upcoming earnings report date is Aug 06, 2024 which is in 77 days.
How were Invitae’s earnings last quarter?
Currently, no data Available
Is Invitae overvalued?
According to Wall Street analysts Invitae’s price is currently Overvalued.
Does Invitae pay dividends?
Invitae does not currently pay dividends.
What is Invitae’s EPS estimate?
Invitae’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invitae have?
Invitae has 286,492,830 shares outstanding.
What happened to Invitae’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Invitae?
Among the largest hedge funds holding Invitae’s share is Baker Bros Advisors LP. It holds Invitae’s shares valued at N/A.
---
Invitae Stock Smart Score
Company Description
Invitae
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
---
NVTAQ Company Deck
---
NVTAQ Earnings Call
Q3 2023
0:00 / 0:00
---
NVTAQ Stock 12 Month Forecast
Average Price Target
―Best Analysts Covering NVTAQ
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+58.23%
assigned a sell rating 6 months ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +58.23% per trade.
---